Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000536988 | SCV000646712 | uncertain significance | Colorectal cancer, susceptibility to, 10 | 2023-12-20 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 306 of the POLD1 protein (p.Arg306Cys). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with POLD1-related conditions. ClinVar contains an entry for this variant (Variation ID: 469393). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt POLD1 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Gene |
RCV001584302 | SCV001812240 | uncertain significance | not provided | 2023-09-20 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed in an individual with high-grade diffuse glioma (Bedics et al., 2022); This variant is associated with the following publications: (PMID: 29717118, 35545820) |
| MGZ Medical Genetics Center | RCV000536988 | SCV002581859 | uncertain significance | Colorectal cancer, susceptibility to, 10 | 2022-07-19 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV003159862 | SCV003909010 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-12-11 | criteria provided, single submitter | clinical testing | The p.R306C variant (also known as c.916C>T), located in coding exon 7 of the POLD1 gene, results from a C to T substitution at nucleotide position 916. The arginine at codon 306 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |